A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT07044050 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma With no Other Specification

Interventions

BIOLOGICAL: allogenic natural killer cells

Sponsor

Emercell SAS